Yahoo Finance Alan Tribe Bought 3.3% More Shares In PYC Therapeutics
PYC Therapeutics Limited (ASX:PYC) shareholders (or potential shareholders) will be happy to see that the Non-Executive Chair of the Board, Alan Tribe, recently bought a whopping AU$5.2m worth of stock, at a price of AU$0.10. While that only increased their holding size by 3.3%, it is still a big swing by our standards.
View our latest analysis for PYC Therapeutics
PYC Therapeutics Insider Transactions Over The Last Year
In fact, the recent purchase by Non-Executive Chair of the Board Alan Tribe was not their only acquisition of PYC Therapeutics shares this year. They previously made an even bigger purchase of AU$14m worth of shares at a price of AU$0.055 per share. Although we like to see insider buying, we note that this large purchase was at significantly below the recent price of AU$0.10. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.
Happily, we note that in the last year insiders paid AU$20m for 324.40m shares. On the other hand they divested 28.18m shares, for AU$2.4m. In the last twelve months there was more buying than selling by PYC Therapeutics insiders. Their average price was about AU$0.063. We don't deny that it is nice to see insiders buying stock in the company. However, we do note that they were buying at significantly lower prices than today's share price. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
PYC Therapeutics is not the only stock insiders are buying. So take a peek at this free list of under-the-radar companies with insider buying.
Does PYC Therapeutics Boast High Insider Ownership?
For a common shareholder, it is worth checking how many shares are held by company insiders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. PYC Therapeutics insiders own about AU$218m worth of shares (which is 45% of the company). Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
So What Does This Data Suggest About PYC Therapeutics Insiders?
The recent insider purchase is heartening. And the longer term insider transactions also give us confidence. But on the other hand, the company made a loss during the last year, which makes us a little cautious. When combined with notable insider ownership, these factors suggest PYC Therapeutics insiders are well aligned, and quite possibly think the share price is too low. One for the watchlist, at least! In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing PYC Therapeutics. Every company has risks, and we've spotted 2 warning signs for PYC Therapeutics you should know about.
But note: PYC Therapeutics may not be the best stock to buy. So take a peek at this free list of interesting companies with high ROE and low debt.
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
